ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Zai Lab Ltd
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$24.06+0.87 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $26.87B
- P/E (TTM)
- –
- Dividend yield
- –
Zai Lab Ltd revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZEJULA | $189.04M | $187.08M | $168.84M | $145.19M | $93.58M | $32.14M | $6.63M | $129.00K | – | – | 41.1% | +1.0% |
| VYVGART / VYVGART Hytrulo | $94.20M | $93.64M | $10.01M | $0 | – | – | – | – | – | – | 20.5% | +0.6% |
| NUZYRA | $60.84M | $43.20M | $21.66M | $5.20M | $3.00K | $0 | – | – | – | – | 13.2% | +40.8% |
| OPTUNE | $48.33M | $40.48M | $46.97M | $47.32M | $38.90M | $16.42M | $6.36M | – | – | – | 10.5% | +19.4% |
| QINLOCK | $35.61M | $28.83M | $19.24M | $14.96M | $11.62M | $402.00K | – | – | – | – | 7.7% | +23.5% |
| XACDURO | $22.91M | $3.31M | $0 | $0 | – | – | – | – | – | – | 5.0% | +593.3% |
| AUGTYRO | $5.54M | $1.09M | $0 | $0 | – | – | – | – | – | – | 1.2% | +409.0% |
| Other | $717.00K | $0 | $0 | – | – | – | – | – | – | – | 0.2% | – |
| Other | – | – | – | – | – | $402.00K | – | – | – | – | – | – |
| VYVGART / VYVGART Hytrulo | – | – | $10.01M | $0 | $0 | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Zai Lab's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.